Batm Advanced Communications Ltd. · LSE:BVC
Batm Advanced Communications — H1 2021 Earnings Presentation
20 slides from Batm Advanced Communications's earnings presentation, August 2021
Slide 1: Interim Results August 2021
Fox 01010101 81070, {010107070975 Interim Results August 2021
Slide 2: Disclaimer
Disclaimer The information contained in this document has largely been extracted from the announcement of the Company’s interim results for the six months ended 30 June 2021. The information contained in this document and the accompanying form of presentation has not been independently verified and
Slide 3: H1 2021 Summary
H1 2021 Summary Momentum of 2020 Significant sales Continued strategic Group revenue grew EBITDA increased by Entered second half of continued into H1 growth in Bio-Medical focus on value by 8% if contribution 325% to $22.7m (H1 year with strong order 2021 division driven by creation saw disposal fr
Slide 4: Group Strategy
Group Strategy BATM brings high-technology solutions to complex, mission-critical applications in the global sectors of bio-medicine and networking BATM Innovation Engine Growth Markets Taking world-leading Delivering Shareholder expertise and IP to Value mass-market success BIO-MEDICAL EPS growth V
Slide 5: Financial Review
101010107 o OT p01070 727 FINANCIAL REVIEW
Slide 6: H1 2021 Financial Summary
H1 2021 Financial Summary H1 2021 H1 2020* Change $m $m Revenue 71.4 77.4 (7.7%) Gross profit 25.7 23.0 +11.7% Gross margin 36.0% 29.7% +630bps Operating profit 20.0 2.4 +733.3% Adj.** operating profit 20.5 2.8 +640.1% EBITDA 22.7 5.3 +325.3% Earnings per share (cents) 2.72¢ 0.36¢ +655.6% Cash and f
Slide 7: Bio-Medical
Bio-Medical H1 2021 H1 2020 H1 2020 H1 2021 Diagnostics Unit 20.0 15.0 17.8 ($000’s) 10.0 5.9 5.0 Revenues 55,071 49,952 0.0 0.8 7.7 Cost of sales 34,185 33,935 Revenue ($m) Operating Profit ($m) Gross profit* 20,886 16,017 H1 2020 H1 2021 Eco-Med Unit 20.0 Gross margin 37.9% 32.1% 15.0 10.0 13.2 Op
Slide 8: Networking & Cyber
Networking & Cyber H1 2021 H1 2020 Networking & Cyber Division ($000’s) 60.0 Revenues 16,377 27,458 50.0 Cost of sales 11,254 20,262 40.0 Gross profit* 5,123 7,196 30.0 Gross margin 31.3% 26.2% 31.3 27.5 26.2 Operating expenses 20.0 - R&D 2,086 2,665 10.0 16.4 11.1 - S&M 2,387 2,513 0.0 - G&A 2,635
Slide 9: Capital Allocation Priorities
Capital Allocation Priorities 3. Returns to 1. Investment 2. Acquisitions Shareholders Our primary use of capital is Targeting strategic Progressive dividend policy investment in research and acquisitions where we see and expect to increase development, our go-to- consolidation opportunities d
Slide 10: Bio-Medical Division Business Review
Business Review BIO-MEDICAL DIVISION DIAGNOSTICS ECO-MED DISTRIBUTION BATM H1 2021 Results 10
Slide 11: Bio-Medical H1 2021 Highlights
Bio-Medical H1 2021 Highlights Diagnostics (Revenue +200%) Growth driven by sustained demand for COVID-19 test kits and instruments Expanded portfolio of COVID-19 tests with launch of a saliva-based PCR test and lateral rapid flow test Customers primarily public health authorities in Europe, M
Slide 12: Bio-Medical Division Outlook
Bio-Medical Division Outlook Sustained momentum expected in Diagnostics throughout 2021 Testing expected to remain a key component of pandemic management measures globally, improving disease monitoring and controls, improving health outcomes and providing a tool to assist in re-opening of econom
Slide 13: Networking & Cyber Division Business Review
Business Review NETWORKING & CYBER DIVISION TELCO SYSTEMS CYBER BATM H1 2021 Results 13
Slide 14: CE & Cyber H1 2021 Highlights
CE & Cyber H1 2021 Highlights Carrier Ethernet Slight increase in revenue from carrier ethernet solutions and services following return to normal business practices in the EMEA region Selected as the preferred supplier by a tier 1 telecommunications operator in APAC to provide demarcation units
Slide 15: NFV H1 2021 Highlights
NFV H1 2021 Highlights Edgility platforms Launched Edgility post- Established two period - new brand of partnerships in EMEA to networking products and boost sales and market services based on NFV presence operating system Significant interest from potential customers – Expanded addressable undergoi
Slide 16: Group Outlook
Group Outlook BATM entered H2 2021 with a strong order book Sustained demand for diagnostics solutions as a key tool in pandemic and disease management Bio-Medical division expected to remain the largest contributor to Group revenues in 2021 NFV sales to contribute to growth from roll-out of
Slide 17: Appendix
Appendix
Slide 18: H1 2021 P&L
H1 2021 P&L H1 2021 H1 2020 ($000’s) % rev. % rev. Revenues 71,448 77,410 Gross profit* 26,009 36.4 23,213 30.0 Operating expenses Sales and marketing expenses 9,215 12.9 10,155 13.1 General and administrative expenses 5,721 8.0 6,222 8.0 Research and development expenses 3,652 5.1 3,893 5.0 Other o
Slide 19: H1 2021 Balance Sheet
H1 2021 Balance Sheet 30 June 2021 30 June 2020 31 December 2020 ($000’s) Cash and financial assets 64,893 44,275 53,378 Total assets 195,936 181,847 200,106 Total liabilities 67,873 76,445 81,343 Net assets 128,063 105,402 118,763 BATM H1 2021 Results 19
Slide 20: H1 2021 Cash Flow
H1 2021 Cash Flow H1 2021 H1 2020 ($000’s) Net cash from (used in) operations (2,255) 4,398 Net cash from (used in) investing activities 17,351 (1,289) Net cash used in financing activities (1,348) (2,567) Net Increase in cash and cash equivalents 11,639 61 Cash and cash equivalents at the beginning
BATM Advanced Communications — H1 2021 Earnings Presentation on 6ix